Cargando…

Peptide-Functionalized Nanoparticles-Encapsulated Cyclin-Dependent Kinases Inhibitor Seliciclib in Transferrin Receptor Overexpressed Cancer Cells

Seliciclib, a broad cyclin-dependent kinases (CDKs) inhibitor, exerts its potential role in cancer therapy. For taking advantage of overexpressive transferrin receptor (TfR) on most cancer cells, T7 peptide, a TfR targeting ligand, was selected as a targeting ligand to facilitate nanoparticles (NPs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Guan Zhen, Lin, Wen Jen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003333/ https://www.ncbi.nlm.nih.gov/pubmed/33803751 http://dx.doi.org/10.3390/nano11030772

Ejemplares similares

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer
por: Coley, H M, et al.
Publicado: (2012)

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
por: Benson, C, et al.
Publicado: (2007)

Characterization of Cyclin E Expression in Multiple Myeloma and Its Functional Role in Seliciclib-Induced Apoptotic Cell Death
por: Josefsberg Ben-Yehoshua, Liat, et al.
Publicado: (2012)

R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair
por: Federico, Mario, et al.
Publicado: (2010)

The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022)

Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer
por: Hassan, Md Sazzad, et al.
Publicado: (2021)

Engineering Peptide Inhibitors of the HFE–Transferrin Receptor 1 Complex
por: Goncalves Monteiro, Daniela, et al.
Publicado: (2022)

Cyclin-dependent kinase inhibitors in malignant hematopoiesis
por: Schirripa, Alessia, et al.
Publicado: (2022)

Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
por: Peyressatre, Marion, et al.
Publicado: (2015)

Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid
por: Porru, Manuela, et al.
Publicado: (2014)

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019)

Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
por: Łukasik, Paweł, et al.
Publicado: (2021)

Cyclin-dependent kinases
por: Malumbres, Marcos
Publicado: (2014)

Overexpression of cyclin‐dependent kinase 1 in esophageal squamous cell carcinoma and its clinical significance
por: Zhang, Han‐Jie, et al.
Publicado: (2021)

Targeted Delivery of siRNA to Transferrin Receptor Overexpressing Tumor Cells via Peptide Modified Polyethylenimine
por: Xie, Yuran, et al.
Publicado: (2016)

Probing Transferrin Receptor Overexpression in Gastric Cancer Mice Models
por: Lodhi, Madeeha Shahzad, et al.
Publicado: (2021)

The Cyclin-Dependent Kinase 5 Inhibitor Peptide Inhibits Herpes Simplex Virus Type 1 Replication
por: Man, Adrian, et al.
Publicado: (2019)

A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
por: Sonawane, Yogesh A., et al.
Publicado: (2016)

Cyclin-Dependent Kinase Inhibitors Induce Apoptosis in Plant Cells
por: Strnad, M., et al.
Publicado: (2001)

Purine Inhibitors of Cyclin-Dependent Kinase and Their Apoptosis and Cytotoxicity Mechanisms
por: Strnad, M., et al.
Publicado: (2001)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020)

Overexpression of Cyclin‐dependent Kinase‐activating CDC25B Phosphatase in Human Gastric Carcinomas
por: Kudo, Yasusei, et al.
Publicado: (1997)

The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer
por: Javed, Aadil, et al.
Publicado: (2023)

Functional Differentiation of Cyclins and Cyclin-Dependent Kinases in Giardia lamblia
por: Kim, Juri, et al.
Publicado: (2023)

Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy
por: Ullah, Zakir, et al.
Publicado: (2009)

Efficient Activation of Reconstructed Rat Embryos by Cyclin-Dependent Kinase Inhibitors
por: Webb, Robin L., et al.
Publicado: (2010)

Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors
por: Suthar, M. P., et al.
Publicado: (2010)

Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice
por: Sallam, Hatem, et al.
Publicado: (2013)

The inhibitors of cyclin-dependent kinases and GSK-3β enhance osteoclastogenesis
por: Akiba, Yosuke, et al.
Publicado: (2015)

Are all cyclin-dependent kinases 4/6 inhibitors created equal?
por: Marra, Antonio, et al.
Publicado: (2019)

The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
por: Tanaka, Tomohito, et al.
Publicado: (2017)

Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
por: Li, Bin-Bin, et al.
Publicado: (2019)

Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
por: Alsfouk, Aisha
Publicado: (2021)

Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment
por: Thoma, Oana-Maria, et al.
Publicado: (2021)

Protein Expression of Cyclin B1, Transferrin Receptor, and Fibronectin Is Correlated with the Prognosis of Adrenal Cortical Carcinoma
por: Moon, Sun Joon, et al.
Publicado: (2020)

Cyclin kinase inhibitors and interferons in lupus
por: Theofilopoulos, A
Publicado: (2003)

Identification of novel inhibitors against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent
por: Hussain, Afzal, et al.
Publicado: (2017)

Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy
por: Abuzaid, Haneen, et al.
Publicado: (2022)

Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex
por: Biglione, Sebastian, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_jnilerafgdueha5ac74k367d94